Status:
COMPLETED
COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management
Lead Sponsor:
Centre Hospitalier Sud Francilien
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
13-25 years
Brief Summary
Lockdown resulting from the COVID-19 pandemic was an unpreceded model of the impact of lifestyle on chronic diseases, especially for adolescents and young adults with type 1 diabetes (T1D) whose lifes...
Detailed Description
Continuous glucose monitoring (CGM) data will be collected from the cloud-based platform, LibreView. Data will be collected for patients from Sud-Francilien hospital (Corbeil-Essonnes, France) and Kr...
Eligibility Criteria
Inclusion
- Type 1 diabetes
- Age between 13 and 25 years
- use of a flash glucose monitoring related to the LibreView cloud platform
- patients follow-up by the diabetes department of Hopital Sud Francilien or the diabetes department of Hôpital Bicêtre.
- patient informed of the study and not having objected to it.
Exclusion
- patients out of France during lockdown
- other type of diabetes
- Duration of diabetes of less than one year
- patient aged under 13 years or above 26 years old
Key Trial Info
Start Date :
January 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 22 2021
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT04669912
Start Date
January 15 2021
End Date
January 22 2021
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France, 91100